BPC-157 + TB-500 (20 mg Blend) Dosage Protocol

Dosing & Reconstitution Overview

This blend pairs BPC-157, a 15-amino-acid fragment derived from a protein found in gastric juice, with TB-500, a synthetic version of the active region of thymosin beta-4. The two are co-formulated in a single lyophilized vial holding 20 mg of total material — split evenly as 10 mg of BPC-157 and 10 mg of TB-500. The figures below are compiled strictly for laboratory and educational reference; they describe how the combination is handled and measured, not a recommendation for use in humans or animals.

For a 20 mg vial, adding 3.0 mL of bacteriostatic water yields a total concentration of ~6.67 mg/mL, which works out to roughly 3.33 mg/mL of each peptide. At that fill, a 0.10 mL draw on a U-100 insulin syringe equals 10 units and delivers about 667 mcg of blend (≈333 mcg of each compound), so the per-unit math stays consistent across the titration steps below.

Standard (Gradual) Titration Schedule

The gradual schedule starts low and steps the daily amount upward over several weeks, giving a slow ramp that many reference protocols favour for tolerability when modelling once-daily subcutaneous administration.

Reconstitution Steps

1. Let the sealed lyophilized vial and the bacteriostatic water reach room temperature, then wipe both stoppers with an alcohol swab.
2. Draw 3.0 mL of bacteriostatic water and inject it slowly down the inside wall of the vial — never directly onto the powder pellet.
3. Swirl gently until both peptides fully dissolve. Do not shake; vigorous agitation can damage the peptide chains.
4. The finished solution should be clear and colourless. Label the vial with the total concentration (~6.67 mg/mL) and the reconstitution date.
5. Store upright under refrigeration between uses and draw each subsequent volume with a fresh sterile syringe.

Advanced (Loading) Schedule

The advanced approach front-loads a higher daily amount for the first four weeks before dropping to a maintenance level. It reaches the top of the typical range at the loading step and is sometimes referenced where a faster cumulative exposure is being modelled.

Supplies Needed

• Blend vials (20 mg): ~2 vials for a 4-week run; ~3 vials for 6 weeks; ~3–4 vials for 8 weeks.
• Insulin syringes (U-100, 1 mL): 28 for 4 weeks, 42 for 6 weeks, 56 for 8 weeks (one fresh syringe per daily draw).
• Bacteriostatic water (10 mL): one bottle covers a 4–6 week run; two bottles for an 8-week schedule.
• Alcohol swabs: a single 100-count box covers 4–6 weeks; two boxes for 8 weeks.

Protocol Overview

• Research goal: model combined cytoprotective and tissue-repair signalling from a BPC-157 / TB-500 pairing.
• Schedule: once-daily subcutaneous administration in the referenced model.
• Dose band: 500–1500 mcg total blend daily (≈250–750 mcg of each peptide).
• Fill: 20 mg lyophilized (10 mg + 10 mg), reconstituted to ~6.67 mg/mL with 3 mL diluent.
• Storage: −20 °C dry; 2–8 °C once reconstituted.

Dosing Protocol Notes

• Begin at the lowest 500 mcg step and hold each level for one to two weeks before stepping up.
• Keep administration on a fixed daily cadence and ideally the same time of day for steady exposure modelling.
• Escalate only after the prior step has been tolerated.
• Most referenced runs sit in the 4–8 week window before pausing to reassess.

Storage Instructions

Keep sealed lyophilized vials at −20 °C, protected from light, where the dry powder stays stable for many months. Once reconstituted, refrigerate at 2–8 °C and use within about 14 days. Allow refrigerated solution to warm slightly before drawing, avoid repeated freeze-thaw cycles, and aliquot if a vial will be sampled many times.

Important Handling Notes

• Use a sterile syringe for every draw and never re-enter the vial with a used needle.
• Rotate handling technique to keep the rubber stopper intact across many punctures.
• Because both peptides share the vial, draw the full daily volume in one pull to keep the split even.
• Document each draw — date, volume, remaining material — for reproducibility.

How It Works

BPC-157 is a stable 15-amino-acid pentadecapeptide fragment isolated from a protein in gastric juice. In preclinical work it has been studied for cytoprotective and tissue-repair activity spanning the gastrointestinal tract, tendons and other musculoskeletal tissue, and the nervous system, with proposed effects on blood-vessel formation. TB-500 is the synthetic active fragment of thymosin beta-4, a 43-amino-acid peptide tied to cell migration, angiogenesis and wound healing. The rationale for pairing them is that their reported repair mechanisms are studied as complementary — BPC-157 leaning toward localized protection and TB-500 toward broader cell-migration and vascular processes.

Reported Benefits & Side Effects

Benefits reported in research

• Wound healing and tendon-repair signalling in preclinical models.
• Anti-inflammatory activity across several tissue types.
• Gastroprotective and ulcer-healing effects attributed mainly to BPC-157.
• A wide safety margin in the available animal studies.

Side effects reported

• Occasional mild injection-site reactions such as redness or itching.
• Rare, transient dizziness or nausea in scattered reports.
• Long-term controlled human safety data remain limited for both compounds.

Injection/Handling Technique (Reference Only)

• Clean the vial stopper and the handling site with alcohol and let both dry.
• Insert subcutaneously at a 45–90° angle using a fine needle (23–25 gauge, 5/8″); aspiration is not required for subcutaneous work.
• Inject slowly and steadily; rotate sites systematically across the abdomen, lateral thigh, upper arm and other approved areas.
• Where a localized site is being modelled, subcutaneous placement near the target area is sometimes referenced when anatomically appropriate.
• Dispose of sharps in an approved container.

References

Related Protocols